Core Viewpoint - MicroPort Scientific Corporation's stock (02252) has seen a rise of over 5%, reaching HKD 30.2, with a trading volume of HKD 130 million, following the announcement of significant order growth for its core products [1] Group 1: Order Volume and Product Performance - As of the announcement date, the cumulative order volume for the company's core products, including laparoscopic, orthopedic, and vascular intervention devices, has exceeded 170 units [1] - The TiMAY laparoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, making it the leading domestic brand in this sector [1] Group 2: International Market Expansion - The TiMAY robot has surpassed 60 overseas orders, with installations across nearly 40 countries and regions, including Asia, Europe, Africa, Oceania, and South America [1] - The company has successfully conducted large-scale clinical surgeries in mainstream hospital systems in countries such as Italy, Belgium, India, Brazil, Argentina, and the UAE [1] Group 3: Milestone Achievements - The company has reached a significant milestone in its global high-end medical market strategy, with the TiMAY robot being commercially deployed in a top-tier medical institution ranked among the world's top two [1] - The successful implementation of a comprehensive intelligent surgical solution has been achieved through both single-port and multi-port series deployments [1]